Ember Health has filed a notice of an exempt offering of securities to raise $1,906,578.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Ember Health is raising $1,906,578.00 in new funding. Sources indicate that as part of senior management Partner, Nicolas Grundmann played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Ember Health
We provide safe, effective ketamine therapy for people seeking relief from depression We founded Ember Health because we were frustrated by the lack of effective medical treatment options for the millions of people struggling with severe depression. We know we share this feeling with the thousands of compassionate mental healthcare professionals who provide critical counsel to their patients. They desire better, more reliable complements to their care. We believe ketamine is a powerful answer to this need: Whereas fewer than 30% of patients on traditional antidepressants realize relief of their depressive symptoms, low-dose infusions of ketamine have shown an average of 75% improvement in depression. While oral antidepressant medication can take six to eight weeks to take effect and have unwanted side effects, ketamine takes effect almost immediately after administration, with minimal, if any, harmful effect.
To learn more about Ember Health, visit http://emberhealth.co/
Contact:
Nicolas Grundmann, Partner
347-547-3258
https://www.linkedin.com/in/nicogrundmann/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.